{"organizations": [], "uuid": "90b00b13d2359c0138ff3e55367ae63bf3c45b3c", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180222.html", "section_title": "Archive News &amp; Video for Thursday, 22 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-neovacs-obtains-us-patent-for-trea/brief-neovacs-obtains-u-s-patent-for-treatment-of-interpheron-alpha-related-conditions-idUSFWN1QC01C", "country": "US", "domain_rank": 408, "title": "BRIEF-Neovacs Obtains U.S. Patent For Treatment Of Interpheron Alpha Related Conditions​", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.089, "site_type": "news", "published": "2018-02-22T14:51:00.000+02:00", "replies_count": 0, "uuid": "90b00b13d2359c0138ff3e55367ae63bf3c45b3c"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-neovacs-obtains-us-patent-for-trea/brief-neovacs-obtains-u-s-patent-for-treatment-of-interpheron-alpha-related-conditions-idUSFWN1QC01C", "ord_in_thread": 0, "title": "BRIEF-Neovacs Obtains U.S. Patent For Treatment Of Interpheron Alpha Related Conditions​", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 22 (Reuters) - NEOVACS SA:\n* ‍HAS BEEN GRANTED BY UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) A PATENT ​\n* ‍PATENT ENTITLED “METHOD FOR TREATING INTERPHERON ALPHA RELATED CONDITIONS”​\n* ‍ASSURES IN THIS COUNTRY PROTECTION OF ITS TECHNOLOGY PLATFORM AT LEAST UNTIL 2032​\n* ‍RESULTS OF PHASE IIB TRIAL IN LUPUS WITH THE IFN KINOID SHOULD BE COMMUNICATED BY JUNE THIS YEAR​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-02-22T14:51:00.000+02:00", "crawled": "2018-02-23T15:51:05.000+02:00", "highlightTitle": ""}